RecruitingNCT05700149

Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma

Sponsor

International Extranodal Lymphoma Study Group (IELSG)

Enrollment

300 participants

Start Date

Apr 11, 2024

Study Type

OBSERVATIONAL

Conditions

Nodal Marginal Zone Lymphoma

Summary

International retrospective observational cohort study aimed to describe a molecular classification for NMZL.

Eligibility

Min Age: 18 Years

Inclusion Criteria4

Male or female adults 18 years or older
Diagnosis of NMZL on lymph node histology after Jan 1st, 2000
Availability of tumor material from lymph node (either frozen or FFPE) collected when the patient was treatment naïve
Availability of the baseline and follow-up annotations

Exclusion Criteria1

\. Nodal spread of a clinically occult extranodal MZL (this must have been ruled out by carefully evaluating the extranodal tissues draining to the involved lymph nodes by imaging or endoscopy)

Locations(36)

University of Miami

Miami, Florida, United States

Weill Cornell Medical

New York, New York, United States

Hematology Center after Prof. Yeolyan

Yerevan, Armenia

University Hospital Centre Zagreb

Zagreb, Croatia

AO SS Antonio e Biagio e C. Arrigo

Alessandria, AL, Italy

Istituto Tumori "Giovanni Paolo II" I.R.C.C.S.

Bari, BA, Italy

ASST Papa Giovanni XXIII

Bergamo, BG, Italy

ASST degli Spedali Civili di Brescia

Brescia, BS, Italy

AOU Policlinico Vittorio Emanuele, Presidio Ferrarotto

Catania, CT, Italy

Azienda Ospedaliero Universitaria di Ferrara

Cona, FE, Italy

Azienda Ospedaliera Universitaria Careggi

Florence, FI, Italy

Azienda Ospedaliera Papardo

Messina, ME, Italy

IRCCS Ospedale San Raffaele

Milan, MI, Italy

IEO Istituto Europeo di Oncologia

Milan, MI, Italy

ASST Grande Ospedale Metropolitano Niguarda

Milan, MI, Italy

Azienda Sanitaria Locale di Pescara

Pescara, PE, Italy

Centro di Riferimento Oncologico

Aviano, PN, Italy

Fondazione IRCCS Policlinico San Matteo

Pavia, PV, Italy

AUSL IRCCS di Reggio Emilia, Arcispedale S. Maria Nuova

Reggio Emilia, RE, Italy

Fondazione PTV - Policlinico Tor Vergata

Rome, RM, Italy

Sapienza University - AOU Policlinico Umberto I

Rome, RM, Italy

Fondazione Policlinico Univeristario A. Gemelli, IRCCS, Università Cattolica S. Cuore

Rome, RM, Italy

ASST dei Sette Laghi - Ospedale di Circolo di Varese

Varese, VA, Italy

IRCCS - Azienda Ospedaliero-Universitaria di Bologna

Bologna, Italy

Azienda Ospedaliera Universitaria Federico II

Napoli, Italy

AOU Maggiore della Carità

Novara, Italy

Portuguese Institute of Oncology

Lisbon, Portugal

Chonnam National University Hwasun Hospital

Hwasun-gun, South Korea

University Hospital Basel

Basel, Switzerland

Oncology Institute of Southern Switzerland and Institute of Oncology Research

Bellinzona, Switzerland

Hôpitaux Universitaires Genevois

Geneva, Switzerland

Kantonsspital St. Gallen

Sankt Gallen, Switzerland

University Hospital Zurich

Zurich, Switzerland

Leicester Royal Infirmary

Leicester, United Kingdom

Norfolk and Norwich University Hospital

Norwich, United Kingdom

Oxford University Hospitals

Oxford, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05700149

Related Trials

Study of SGR-1505 in Mature B-Cell Neoplasms

NCT0554401936 locations

Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

NCT042237651 location

Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)

NCT067969981 location